Elimination of CD4^lowHLA-G⁺ T cells overcomes castration-resistance in prostate cancer therapy.

ABSTRACT: Androgen deprivation therapy (ADT) is a main treatment for prostate cancer (PCa) but the disease often recurs and becomes castration-resistant in nearly all patients. Recent data implicate the involvement of immune cells in the development of this castration-resistant prostate cancer (CRPC). In particular, T cells have been found to be expanded in both PCa patients and mouse models shortly after androgen deprivation. However, whether or which of the T cell subtypes play an important role during the development of CRPC is unknown. Here we identified a novel population of CD4^lowHLA-G⁺ T cells that undergo significant expansion in PCa patients after ADT. In mouse PCa models, a similar CD4^low T cell population expands during the early stages of CRPC onset. Thes

SUBMITTER: Wang C 

PROVIDER: S-EPMC6218442 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature